comparemela.com

Latest Breaking News On - Roche india - Page 15 : comparemela.com

Delhi High Court Seeks Centre s Response On How It Intends To Obtain Supply Of Tocilizumab Drug

Delhi High Court Seeks Centre s Response On How It Intends To Obtain Supply Of Tocilizumab Drug
livelaw.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from livelaw.in Daily Mail and Mail on Sunday newspapers.

DRDO s 2DG Covid medicine to launch next week: Crucial in recovery of patients

12:59 PM Though India is currently experiencing a oxygen and vaccine shortage, there is some good news on the horizon. The Defense Research and Development Organization has announced that the first batch of 2-deoxy-D-glucose (2-DG) medicine for the treatment of mild to serious Covid-19 cases will be available next week. “The first batch of 10,000 doses of 2DG medicine for the treatment of COVID-19 infected patients will be launched early next week and given to patients,” the official said. “The pharma companies are working to increase the production of the medication for potential use. A team of DRDO scientists, led by Dr. Anant Narayan Bhatt, created the drug “officials have said.  2-DG (2-deoxy-D-glucose), an anti-COVID-19 therapeutic application of the drug, was created in cooperation with Dr Reddys Laboratories (DRL) in Hyderabad by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of the Defence Research and Development O

Will antibody cocktail of Roche reduce demand for Tocilizumab: HC

The Delhi High Court has asked the Centre whether demand for COVID-19 drug Tocilizumab, which is in short supply, would be reduced if drug major Roche provides its new antibody cocktail that has been approved for emergency use in India for coronavirus patients. The court also asked the Centre what quantities of the antibody cocktail would be required for the purpose of reducing demand for Tocilizumab. The query was posed to the government by Justice Prathiba M Singh after Roche India, which supplies Tocilizumab in India, told the court it can only endeavour to supply the medicine and cannot assure to meet the market demand for the same, even though patients are willing to pay for it.

Will antibody cocktail of Roche reduce demand for Tocilizumab?  HC asks Centre

Will antibody cocktail of Roche reduce demand for Tocilizumab?  HC asks Centre The court also asked the Centre what quantities of the antibody cocktail would be required for the purpose of reducing demand for Tocilizumab. Share Via Email   |  A+A A- Health workers and volunteers in personal protective suits wait to receive patients outside a COVID-19 hospital that was set up at a Sikh Gurdwara in New Delhi. (Photo | AP) By PTI NEW DELHI: The Delhi High Court has asked the Centre whether demand for COVID-19 drug Tocilizumab, which is in short supply, would be reduced if drug major Roche provides its new antibody cocktail that has been approved for emergency use in India for coronavirus patients.

Will antibody cocktail of Roche reduce demand for Tocilizumab: Delhi High Court

Will antibody cocktail of Roche reduce demand for Tocilizumab: Delhi High Court SECTIONS Last Updated: May 14, 2021, 01:02 PM IST Share Synopsis The query was posed to the government by Justice Prathiba M Singh after Roche India, which supplies Tocilizumab in India, told the court it can only endeavour to supply the medicine and cannot assure to meet the market demand for the same, even though patients are willing to pay for it. Getty Images The court noted that the global manufacturing figures of the drug have not been filed before it by Roche despite specific directions. The Delhi High Court has asked the Centre whether demand for COVID-19 drug Tocilizumab, which is in short supply, would be reduced if drug major Roche provides its new antibody cocktail that has been approved for emergency use in India for coronavirus patients. The court also asked the Centre what quantities of the antibody cocktail would be required for the purpose of reducing demand for Tocilizumab.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.